Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07112612
What this trial is testing

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
MRDProstate CancermHSPC
Anhui Medical University 50
Early research (Phase 1)Study completedNCT04477512
What this trial is testing

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Washington University School of Medicine 18
Large-scale testing (Phase 3)Looking for participantsNCT07723248
What this trial is testing

Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
ORIC Pharmaceuticals 600
Not applicableStudy completedNCT00456144
What this trial is testing

Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

Who this might be right for
Prostate Cancer
Massachusetts General Hospital 36
Early research (Phase 1)Study completedNCT00148928
What this trial is testing

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

Who this might be right for
Neoplasms, Prostate
GlaxoSmithKline 25
Not applicableStudy completedNCT05149131
What this trial is testing

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Bayer 960
Post-approval studies (Phase 4)UnknownNCT04601441
What this trial is testing

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Kindai University 100
Not applicableNot Yet RecruitingNCT07804030
What this trial is testing

AI-Assisted Patient Support in mHSPC

Who this might be right for
Metastatic Prostate Cancer
Fudan University 160
Not applicableLooking for participantsNCT06334120
What this trial is testing

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Who this might be right for
Non-metastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate Cancer
Bayer 600
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd. 180
Testing effectiveness (Phase 2)Looking for participantsNCT05915442
What this trial is testing

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Who this might be right for
Oligometastatic Prostate Cancer
Catherine Spina 23
Testing effectiveness (Phase 2)Study completedNCT01875250
What this trial is testing

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 38
Not applicableLooking for participantsNCT06306612
What this trial is testing

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

Who this might be right for
Prostate Cancer
RenJi Hospital 192
Testing effectiveness (Phase 2)Looking for participantsNCT07190300
What this trial is testing

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals 181
Not applicableNot Yet RecruitingNCT07806591
What this trial is testing

Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer 50
Early research (Phase 1)Ended earlyNCT05733351
What this trial is testing

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Emory University 4
Testing effectiveness (Phase 2)Looking for participantsNCT05914116
What this trial is testing

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
DualityBio Inc. 862
Large-scale testing (Phase 3)Active Not RecruitingNCT04557059
What this trial is testing

Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Pharmaceutica N.V., Belgium 691
Testing effectiveness (Phase 2)UnknownNCT02913859
What this trial is testing

Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University Hospital Sestre Milosrdnice 60
Not applicableActive Not RecruitingNCT07344779
What this trial is testing

Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Bayer 1,600
Next Page